© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site
News Preview
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz
Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ advanced continuous manufacturing technology
......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec und Sandoz entwickeln ihre strategische Partnerschaft weiter und vereinbaren einen möglichen Verkauf des Just – Evotec Biologics Standorts in Toulouse
News Preview
Evotec SE und Sandoz AG haben ein nicht-bindendes Term Sheet über den geplanten Verkauf von Just – Evotec Biologics EU in Toulouse an Sandoz unterzeichnet
Im Rahmen der vorgeschlagenen Vereinbarung würde Evotec ihre Ressourcen zur Herstellung von Biosimilars übertragen, um Sandoz die Produktion von Biosimilar-Arzneimitteln unter Verwend......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site
News Preview
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the sig......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec SE und Sandoz AG planen möglichen Verkauf von Just – Evotec Biologics Standort Toulouse
News Preview
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Ad hoc: Evotec SE und Sandoz AG planen möglichen Verkauf von Just – Evotec Biologics Standort Toulouse
Hamburg – Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt die Unterze......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
30.07.2025
FYB
LISTED
XETR
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
News Preview
Press Release // July 30, 2025
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results of the first half of the 2025 fiscal year on Au......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 3. Quartal 2025 bekannt
News Preview
Pressemitteilung // 30. Juli 2025
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2025 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 3. Quartal 2025 bekannt
Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) plant die Ergebnisse des ersten Halbjahres 2025 am 13. August ......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
News Preview
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a considerati...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
News Preview
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUnder the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technologyThe deal terms in...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
CELC
LISTED
NASDAQ
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset incidence across several different cancer types. According to the Cancer Discovery study from the National Canc...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
DBV
LISTED
EURONEXT
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
News Preview
Châtillon, France, July 29, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
DBV
LISTED
EURONEXT
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
News Preview
Châtillon, France, July 29, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
HNSA
LISTED
STO
Hansa Biopharma announces key executive appointments to support continued growth
News Preview
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.07.2025
HNSA
LISTED
STO
Hansa Biopharma announces key executive appointments to support continued growth
News Preview
LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer and Corporate Secretary, effective August 4; Sandra Frithiof has been appointed Chief Human Resources Officer (CHRO), effective August 4; and Kerstin Falck...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
CLARI
LISTED
EURONEXT
2025 Half-Year results
News Preview
The 2025 interim financial report, including the interim management report and the condensed consolidated interim financial statements at 30 June 2025, is available on the company’s website www.clariane.com. The condensed interim consolidated financial statements were approved by the Board of Directors at its meeting on 29 July 2025 and were subjec...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
EAPI
LISTED
EURONEXT
First-half 2025 results
News Preview
Press Release Paris, 29th July 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
REC
LISTED
EURONEXT
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
News Preview
Milan, 29th July 2025 – The Board of Directors of Recordati S.p.A. approved the interim financial statements as of June 30, 2025, pursuant to Art. 154-ter of Italian Legislative Decree 58/1998 and subsequent amendments, prepared in accordance with said Decree and the CONSOB Issuers Regulation. The statements were prepared in accordance with Interna...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.07.2025
EUZ
LISTED
XETR
Eckert & Ziegler wird US-Hersteller für Archeus' Radiopharmazeutikum der nächsten Generation ART-101
News Preview
Berlin, Deutschland, 29. Juli 2025. Eckert & Ziegler (ISIN DE0005659700) und Archeus Technologies (Archeus), ein Unternehmen, das verschiedene radiopharmazeutische Therapien entwickelt, haben einen Rahmenvertrag über die Auftragsfertigung des neuartigen Wirkstoffs ART-101 geschlossen. Die Kooperation unterstützt die bevorstehende Phase-1-Studie......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.07.2025
EUZ
LISTED
XETR
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
News Preview
Berlin, Germany, 29 July 2025. Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 cli......
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
SLP
LISTED
NASDAQ
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the I...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
RXRX
LISTED
NASDAQ
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
News Preview
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
DBV
LISTED
EURONEXT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
News Preview
AMF Regulated InformationChâtillon, France, July 28, 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.07.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.07.2025 / 16:05 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.07.2025
EUZ
LISTED
XETR
Kapitalerhöhung eingetragen. Aktiensplit in Vorbereitung.
News Preview
Berlin, 28. Juli 2025. Die Hauptversammlung der Eckert & Ziegler SE (ISIN DE0005659700) hatte am 18. Juni 2025 eine Kapitalerhöhung aus Gesellschaftsmitteln um 42.343.864 € auf 63.515.796 € beschlossen. Die Kapitalerhöhung wurde am 25. Juli 2025 in das Handelsregister eingetragen und damit wirksam. Das Grundkapital der Gesellschaft hat sich dad......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.07.2025
EUZ
LISTED
XETR
Capital Increase Entered in the Commercial Register. Share Split in Preparation.
News Preview
Berlin, July 28, 2025. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. The capital increase was entered in the commercial register on 25 July 2025 and thus became effective. As a result, the company's share capital......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.07.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - from First Berlin Equity Research GmbH
28.07.2025 / 13:46 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain......
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
LEGN
LISTED
NASDAQ
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
News Preview
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
BAVA
LISTED
CPH
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation – SLP
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
So What: If you purchased Simulati...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
CELC
LISTED
NASDAQ
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
News Preview
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
ATAI
LISTED
NASDAQ
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
News Preview
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment as...
Themefolio
Profiler
Peergroup
© ActuNews
25.07.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential m...
Themefolio
Profiler
Peergroup
© ActuNews
25.07.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 10 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 250.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om h...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
NUTX
LISTED
NASDAQ
Securities Fraud Investigation Into Nutex Health Inc. (NUTX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON NUTEX HEAL...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2025
SOBI
LISTED
STO
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
News Preview
Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission decision expected by Q4 2025STOCKHOLM, July 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
News Preview
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to th...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2025
RAY B
LISTED
STO
RaySearch to present innovative news in RayStation, RayCare, and RayIntelligence at AAPM 2025
News Preview
STOCKHOLM, July 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce its participation at AAPM in Washington, D.C., July 27-30, where state of the art innovations under the global campaign Coding Energy to End Cancer will be presented. Attendees can take part in demonstrations of the treatment planning system RayStation®...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
SOBI
LISTED
STO
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
News Preview
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years....
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2025
INDV
LISTED
NASDAQ
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Autho...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
NUTX
LISTED
NASDAQ
Nutex Health Inc. (NUTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NUTEX HEALTH INC. (NUTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
NUTX
LISTED
NASDAQ
Securities Fraud Investigation Into Nutex Health Inc. (NUTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON NUTEX HEALTH INC. (NUTX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO R...
Themefolio
Profiler
Peergroup
© ActuNews
24.07.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 7 convertible bonds in Oxurion resulting in a EUR 175,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
24.07.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 7 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 175.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
BAVA
LISTED
CPH
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
News Preview
COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira....
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
DFTX
LISTED
NASDAQ
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30,...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
ICLR
LISTED
NASDAQ
ICON Announces Results of Annual General Meeting
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
ICLR
LISTED
NASDAQ
ICON Reports Second Quarter 2025 Results
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the second quarter ended June 30, 2025.
CEO, Dr. Steve Cutler commented, “ICON made solid progress in quarter two despite the continuing challenges within the clinical development and macro-economic...
Themefolio
Profiler
Peergroup
© ActuNews
23.07.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 5 convertible bonds in Oxurion resulting in a EUR 125,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
23.07.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 5 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 125.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
23.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on July 23, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
23.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 23 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2025
INDV
LISTED
NASDAQ
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
News Preview
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare res...
Themefolio
Profiler
Peergroup
© Newsfile
23.07.2025
COPN
LISTED
SIX
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
News Preview
Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N...
Themefolio
Profiler
Peergroup
© ActuNews
22.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 22 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© ActuNews
22.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 22, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on July 18, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
TEM
LISTED
NASDAQ
Tempus to Report Second Quarter 2025 Financial Results on August 8
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company’s quarterly earnings will be released the same day.
The call will f...
Themefolio
Profiler
Peergroup
© ActuNews
22.07.2025
OXUR
LISTED
EURONEXT
Oxurion overweegt een strategie voor diversificatie van zijn kasmiddelen in digitale activa in het kader van een indicatieve overeenkomst van EUR 10 miljoen met zijn belangrijkste investeerder
News Preview
Deze stap kadert in een langetermijnstrategie voor financiële consolidatie en groeiondersteuning.
Oxurion start onderhandelingen met Atlas Special Opportunities voor een nieuw converteerbaar obligatieprogramma van in totaal €10 miljoen, in schijven van €1 miljoen, converteerbaar met een premie van 10% ten opzichte van het...
Themefolio
Profiler
Peergroup
© ActuNews
22.07.2025
OXUR
LISTED
EURONEXT
Oxurion envisage de lancer une stratégie de diversification de sa trésorerie en actifs numériques dans le cadre d'un accord indicatif de 10 M EUR avec son principal investisseur
News Preview
Cette initiative s'inscrit dans une stratégie long terme de consolidation financière et de soutien à la croissance.
Oxurion rentre en négociation avec Atlas Special Opportunities pour un nouveau programme d'obligation convertibles d'un total de 10M€ par tranches de 1M€ convertible avec une prime d...
Themefolio
Profiler
Peergroup
© ActuNews
22.07.2025
OXUR
LISTED
EURONEXT
Oxurion plans to launch a treasury diversification strategy into digital assets under a EUR 10M indicative agreement with its main investor
News Preview
This initiative is part of a long-term strategy for financial consolidation and growth support.
Oxurion enters negotiations with Atlas Special Opportunities for a new €10 million convertible bond program, in €1 million tranches, convertible with a 10% premium over the 15-day volume-weighted average price (VWAP)
The proceeds f...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
BIOA B
LISTED
STO
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
News Preview
STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous formulation for maintenance dosing, at the Alzheimer's Association International Conference (AAIC), being held i...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
BIOA B
LISTED
STO
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
News Preview
STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous formulation for maintenance dosing, at the Alzheimer's Association International Conference (AAIC), being held i...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
